Lasso-shaped molecule is a new type of broad-spectrum antibiotic分子筛状的分子是一种新型的广谱抗生素。NATUREIF48.52025-03-260PRE
Multi-year analysis of the global preclinical antibacterial pipeline: trends and gapsANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52024-08-073OAAI
Reply to Kaye and Belley, Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too! REPLYANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52022-04-190OA
Recent advances and challenges in antibacterial drug development: EditorialADMET AND DMPKIF4.32022-03-043OAAI
Small Molecular Weapons against Multi-Drug ResistanceACCOUNTS OF CHEMICAL RESEARCHIF17.72021-07-066PREAI
The small-molecule antibiotics pipeline: 2014-2018NATURE REVIEWS DRUG DISCOVERYIF101.82019-08-1448PRE
Analysis of the clinical antibacterial and antituberculosis pipelineLANCET INFECTIOUS DISEASESIF312019-02-01171OAAI
What is an ideal antibiotic? Discovery challenges and path forwardBIOCHEMICAL PHARMACOLOGYIF5.62017-06-01170PREAI
Fosfomycin: Mechanism and ResistanceCOLD SPRING HARBOR PERSPECTIVES IN MEDICINEIF10.12017-01-06233OAAI
Appropriate Targets for Antibacterial DrugsCOLD SPRING HARBOR PERSPECTIVES IN MEDICINEIF10.12016-09-0654OAAI
Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1ANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52016-02-0125OA
Viable screening targets related to the bacterial cell wallANTIMICROBIAL THERAPEUTICS REVIEWS: THE BACTERIAL CELL WALL AS AN ANTIMICROBIAL TARGETIF02012-12-2660PREAI
Multitarget ligands in antibacterial research: progress and opportunitiesEXPERT OPINION ON DRUG DISCOVERYIF4.92012-12-1960PRE
Are natural products still the best source for antibacterial discovery? The bacterial entry factorEXPERT OPINION ON DRUG DISCOVERYIF4.92008-04-2869PREAI
Novel broad spectrum β-lactamase inhibitorsEXPERT OPINION ON THERAPEUTIC PATENTSIF4.62007-10-019PREAI
Multi-targeting by monotherapeutic antibacterials (vol 6, pg 41, 2007)NATURE REVIEWS DRUG DISCOVERYIF101.82007-02-0110OAAI